Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer

Yoshihama, Tomoko; Kuroda, Yoshio; Chiyoda, Tatsuyuki; Takahashi, M.; Yoshimura, Takuma; Saotome, Keiko; Nanki, Yoshiko; Sakai, Kensuke; Kobayashi, Yusuke; Yamagami, Wataru; Aoki, Daisuke

doi:10.1007/s10147-022-02212-x

Cited by 6 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the patient population in the Ola group included many cases of unknown HR status, the distribution of histopathologic types in this study was approximately 60% (29 patients) HGSC, and the response rate to chemotherapy was 44% (26 patients) PR, making it less likely than other studies to include many HRD cases or super-responders, such as patients with BRCA mutations. Studies from Japan and the Asian population reported that the duration of response to Ola might be longer than that observed in previous studies on populations restricted to Japanese and Asian patients, such as those by Yoshihama et al (15.3 months; 95% CI, 9.0-21.6 months) [18] and Gao et al (16.1 months; 95% CI, 13.3-18.3 months) [19]. Therefore, ethnic specificity may be a factor in the longer duration of Ola response in the target population in our multicenter analysis.…”

Section: Discussioncontrasting

confidence: 55%

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations

Nakanishi

Toyoshima

Ueno

et al. 2023

Cancers

View full text Add to dashboard Cite

The use of angiogenesis inhibitors and poly ADP-ribose polymerase inhibitors following multi-agent chemotherapy, including platinum-based agents, has become the standard treatment for platinum-sensitive recurrent ovarian cancer (PSROC). However, the optimal maintenance therapy and selection criteria for these patients remain unclear. Thus, this study aimed to optimize the treatment options and selection criteria for patients with PSROC. The clinical data of 51 patients with PSROC admitted to Nippon Medical School Chiba Hokusoh Hospital and Nippon Medical School Hospital were retrospectively collected. The log-rank test was used for the survival analysis, and Cox proportional hazard regression analysis was used for the multivariate survival analysis. Of the 51 patients, 17 received maintenance therapy with bevacizumab (Bev), and 34 received olaparib (Ola). Recurrence-free survival (RFS) was significantly prolonged in the Ola group (27 months; 95% confidence interval (CI), 19–NA months) compared with that in the Bev group (9 months; 95% CI, 5–22 months; p = 0.000103). The efficacy of Ola was independent of background factors, including response to previous chemotherapy, homologous recombination status, histological type, or laboratory data. Ola is superior to Bev as PSROC maintenance therapy, especially in Japanese and Asian populations.

show abstract

Section: Discussioncontrasting

confidence: 55%

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations

Nakanishi

Toyoshima

Ueno

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Olaparib (Lynparza ® , developed by AstraZeneca, Cambridge, UK) was the first PARPi approved in 2014 by the European Medicines Agency (EMA) and by the Food and Drug Administration (FDA) in the United States for use as a single agent in the clinic. It showed a favorable response in patients with germline BRCA1/2-mutated advanced, recurrent ovarian cancer, and for maintenance treatment of adult patients with recurrent gynecologic cancers [ 86 , 87 , 88 , 89 , 90 ]. To date, three additional PARPi have been approved by the FDA.…”

Section: Development Of Clinically Relevant Parp Inhibitorsmentioning

confidence: 99%

BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy

Soni

Lin

Mladenov

et al. 2022

Cancers

View full text Add to dashboard Cite

BMN673 is a relatively new PARP inhibitor (PARPi) that exhibits superior efficacy in vitro compared to olaparib and other clinically relevant PARPi. BMN673, similar to most clinical PARPi, inhibits the catalytic activities of PARP-1 and PARP-2 and shows impressive anticancer potential as monotherapy in several pre-clinical and clinical studies. Tumor resistance to PARPi poses a significant challenge in the clinic. Thus, combining PARPi with other treatment modalities, such as radiotherapy (RT), is being actively pursued to overcome such resistance. However, the modest to intermediate radiosensitization exerted by olaparib, rucaparib, and veliparib, limits the rationale and the scope of such combinations. The recently reported strong radiosensitizing potential of BMN673 forecasts a paradigm shift on this front. Evidence accumulates that BMN673 may radiosensitize via unique mechanisms causing profound shifts in the balance among DNA double-strand break (DSB) repair pathways. According to one of the emerging models, BMN673 strongly inhibits classical non-homologous end-joining (c-NHEJ) and increases reciprocally and profoundly DSB end-resection, enhancing error-prone DSB processing that robustly potentiates cell killing. In this review, we outline and summarize the work that helped to formulate this model of BMN673 action on DSB repair, analyze the causes of radiosensitization and discuss its potential as a radiosensitizer in the clinic. Finally, we highlight strategies for combining BMN673 with other inhibitors of DNA damage response for further improvements.

show abstract

“…17 epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as the treatment of deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer. 20 OLA was developed in the form of tablets or capsules with anhydrous crystalline form A. 21,22 However, crystalline patents of OLA (including form A) will expire in 2027, and the development of amorphous forms is an alternative way to evade crystalline patents.…”

Section: ■ Introductionmentioning

confidence: 99%

“…Olaparib (OLA, Scheme ) is the first marketed poly ADP ribose polymerase (PARP) inhibitor worldwide, which has consistently ranked as the first in sales among PARP inhibitors on the market. , OLA can capture PARP on DNA, inhibit DNA repair pathways, and lead to tumor cell apoptosis. − Currently, it has been approved by FDA for the maintenance treatment of patients with platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as the treatment of deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer . OLA was developed in the form of tablets or capsules with anhydrous crystalline form A. , However, crystalline patents of OLA (including form A) will expire in 2027, and the development of amorphous forms is an alternative way to evade crystalline patents.…”

Section: Introductionmentioning

confidence: 99%

Effect of Polyamorphism on the Morphology, Dissolution, and Stability of Olaparib

Gao,

Dai,

et al. 2024

Crystal Growth & Design

View full text Add to dashboard Cite

Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer

Cited by 6 publications

References 8 publications

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations

BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy

Effect of Polyamorphism on the Morphology, Dissolution, and Stability of Olaparib

Contact Info

Product

Resources

About